Nathan Smith is a distinguished finance executive with more than 25 years of experience in the biotechnology and healthcare industries. Holding a Bachelor’s degree in Accounting from the University of Michigan and an MBA from the Wharton School of the University of Pennsylvania, Nathan began his career at Deloitte & Touche, where he honed his expertise in audit and financial advisory services for life sciences clients. He later advanced to senior finance roles at Genentech and Illumina, overseeing financial planning, mergers and acquisitions, and capital raises that fueled multibillion-dollar growth initiatives. As Chief Financial Officer of CareDx, Inc. from 2020 to 2023, Nathan spearheaded the company’s financial strategy during a transformative period marked by accelerated revenue growth and innovation in transplant diagnostics. He led the execution of key financing transactions, including a $300 million convertible notes offering, optimized cost structures to improve profitability, and supported the expansion of CareDx’s AlloSure and AlloMap testing platforms, contributing to a tripling of annual revenues to over $400 million. His leadership ensured robust financial reporting and compliance amid regulatory scrutiny, positioning CareDx as a leader in precision medicine. Post-CareDx, Nathan advises venture-backed healthcare startups and serves on the boards of several medtech companies, leveraging his track record of delivering sustainable financial performance in high-growth environments.